Trial · NCT02065687
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-free Survival (PFS) (Phase II) | From date of study entry to time of progression or death, whichever occurs first, assessed up to 5 years | All patients | Months | MEDIAN |
| PRIMARY | Overall Survival (OS) (Phase II and III) | From date of study entry to time of death or the date of last contact, assessed up to 5 years | All patients. | Months | MEDIAN |
| SECONDARY | Proportion of Patients Responding to Therapy | During study treatment, up to 5 years. | Evaluable for response | percentage of patients | NUMBER |
| SECONDARY | Duration of Response by Treatment | From the date of response to disease progression, death, or date last seen assessed up to 5 years | Patients who responded | Months | MEDIAN |
| SECONDARY | Overall Survival (OS) (Phase II) | From date of study entry to time of death or the date of last contact, assessed up to 5 years. | All patients | Months | MEDIAN |
| SECONDARY | Progression Free Survival (PFS) (Phase III) | From date of study entry to time of progression or death, whichever occurs first, assessed up to 5 years | All patients. | Months | MEDIAN |
| SECONDARY | Number of Participants With Grade 3 or Higher Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4 | Up to 5 years | All patients. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Level of Obesity | Up to 5 years | All patients | proportion of participants obese | NUMBER |
| OTHER_PRE_SPECIFIED | Metabolic Factor Levels | Up to 5 years | |||
| OTHER_PRE_SPECIFIED | Incidence of PIK3 Mutations/Amplifications | Up to 5 years | |||
| OTHER_PRE_SPECIFIED | Expression of MATE 2 | Up to 5 years | |||
| OTHER_PRE_SPECIFIED | Levels of Key Targets of the Metformin/mTOR Signaling Pathway | Up to 5 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02065687/outcomes